Literature DB >> 22293625

Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma.

L Mitchell1, S W Dow, J E Slansky, B J Biller.   

Abstract

Characterization of the tumor microenvironment, particularly the immune cells that infiltrate tumors, provides important predictive and prognostic information in humans with lymphoma and other types of cancer. Tumor associated T lymphocytes have not been previously described in dogs with lymphoma. Therefore, we investigated the phenotype and function of T cells in the lymph nodes of dogs with B cell Non-Hodgkin's lymphoma (NHL), as well as the function of T cells in circulation of these dogs. We found that CD4+ and CD8+ T lymphocytes were few in number and minimally responsive to mitogenic stimuli compared to T cells in lymph nodes of normal dogs. Additionally, regulatory T cells (Treg) were significantly increased in tumor tissues compared to lymph nodes of healthy dogs. To better understand cell mediated antitumor immune responses we developed a non-radioactive assay to measure cytotoxic T lymphocyte (CTL) mediated killing of autologous tumor cells. Using this assay, we found that spontaneous CTL activity in the blood of dogs with lymphoma improved significantly following induction of tumor remission using doxorubicin. Coincident with the improvement in CTL activity, circulating Treg numbers were significantly decreased compared to pretreatment levels. We conclude from these studies that CTL activity in dogs with lymphoma can be significantly improved following induction of tumor remission using chemotherapy, as assessed using a new non-radioactive CTL assay. Copyright Â
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293625     DOI: 10.1016/j.vetimm.2012.01.006

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  5 in total

1.  Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma.

Authors:  Alessandra Gavazza; George Lubas; Arthur Fridman; Daniela Peruzzi; Joseph A Impellizeri; Laura Luberto; Emanuele Marra; Giuseppe Roscilli; Gennaro Ciliberto; Luigi Aurisicchio
Journal:  Hum Gene Ther       Date:  2013-08       Impact factor: 5.695

2.  The canine MHC class Ia allele DLA-88*508:01 presents diverse self- and canine distemper virus-origin peptides of varying length that have a conserved binding motif.

Authors:  Peter Ross; Paige S Nemec; Alexander Kapatos; Keith R Miller; Jennifer C Holmes; Steven E Suter; Adam S Buntzman; Erik J Soderblom; Edward J Collins; Paul R Hess
Journal:  Vet Immunol Immunopathol       Date:  2018-02-02       Impact factor: 2.046

3.  Dissecting the regulatory microenvironment of a large animal model of non-Hodgkin lymphoma: evidence of a negative prognostic impact of FOXP3+ T cells in canine B cell lymphoma.

Authors:  Dammy Pinheiro; Yu-Mei Chang; Hannah Bryant; Balazs Szladovits; Tim Dalessandri; Lucy J Davison; Elizabeth Yallop; Emily Mills; Chiara Leo; Ana Lara; Anneliese Stell; Gerry Polton; Oliver A Garden
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

Review 4.  Canine cancer immunotherapy studies: linking mouse and human.

Authors:  Jiwon S Park; Sita S Withers; Jaime F Modiano; Michael S Kent; Mingyi Chen; Jesus I Luna; William T N Culp; Ellen E Sparger; Robert B Rebhun; Arta M Monjazeb; William J Murphy; Robert J Canter
Journal:  J Immunother Cancer       Date:  2016-12-20       Impact factor: 13.751

5.  Long-term survival of a feline with non-T/B large granular lymphocyte lymphoma treated with chemotherapy and activated lymphocyte therapy.

Authors:  Shimon Furusato; Yu Tamura; James K Chambers; Takahiro Ushigusa; Yu Tsuyama
Journal:  Open Vet J       Date:  2022-05-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.